1. Update on Medical Management of Pulmonary Arterial Hypertension
- Author
-
Alexander E. Sherman, Richard N. Channick, and Rajan Saggar
- Subjects
Heart Failure ,Pulmonary Arterial Hypertension ,medicine.medical_specialty ,business.industry ,Hypertension, Pulmonary ,Prostacyclin ,General Medicine ,Exercise capacity ,medicine.disease ,Pulmonary hypertension ,Nitric oxide ,chemistry.chemical_compound ,chemistry ,Internal medicine ,Cardiology ,Humans ,Right ventricular failure ,Medicine ,In patient ,Cardiology and Cardiovascular Medicine ,business ,Endothelin receptor ,Antihypertensive Agents ,Rare disease ,medicine.drug - Abstract
Pulmonary arterial hypertension is a rare disease characterized by pulmonary microvasculature remodeling leading to right ventricular failure and death. Medical management of pulmonary hypertension has grown increasingly complex as more therapeutic agents have been developed. Evolving treatment strategies leveraging the endothelin, nitric oxide, and prostacyclin pathways lead to improved exercise capacity and outcomes in patients; however, significant opportunities for advancement remain.
- Published
- 2022